Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors including [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors. It is grouped under the following drug class(es): Kinase inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include qinlock, ripretinibum and DCC2618. Its PubChem CID is 71584930.
Ripretinib
| CAS No | 1442472-39-0 |
|---|---|
| Molecular Formula | C24H21BrFN5O2 |
| Molecular Weight | 510.4 g/mol |
| Synonyms | 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors including [sunitinib] and [imatinib].
The listed CAS number is 1442472-39-0.
The listed molecular formula is C24H21BrFN5O2.
The listed molecular weight is 510.4 g/mol.
1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea.
The source lists qinlock, ripretinibum and DCC2618.